Remove 2019 Remove Clinical Trials Remove Epilepsy Remove Information
article thumbnail

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NHS To Launch Its First Evidence-Based Cannabis Patient Data Registry This Week – Cannabis Business Executive

SpeedWeed

Dr Daniel Couch, Medical Lead at the UK Centre For Medicinal Cannabis welcomed the move as a sensible way of establishing an evidence base that will inform prescribing and future Randomised Controlled Trials (RCT). Private Clinic Happy To Help. “For For background on its launch see here ). Boost For NHS Cannabis Prescribing .

Data 52
article thumbnail

What is CBN (Cannabinol)? How does the natural byproduct of THC work?

The Cannigma

In a 2019 animal study, CBN isolate was reported to relieve musculoskeletal pain. When CBN was studied without barbiturates (prescription sedative medications typically used for epilepsy), the combination of CBN and THC produced greater sedation together than either cannabinoid alone. What can the current clinical trials tell us?

THC 140
article thumbnail

BBC Report: EU Approves , “Epidyolex” GW Pharmaceuticals

Cannabis Law Report

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. September 23, 2019. What do experts say?

article thumbnail

Use of Cannabis-based medicinal products: NICE guidelines

Cannabis Law Report

NICE guideline [NG144] Published date: November 2019. Finding more information and committee details. Severe treatment-resistant epilepsy. Severe treatment-resistant epilepsy. People have the right to be involved in discussions and make informed decisions about their care, as described in your care. Spasticity.

article thumbnail

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. 646) 421-9523.